Previous 10 | Next 10 |
Building on Organon’s Prior FP2030 Commitment, the Company Announces $30 Million in New Funding to Fuel Global Action and Community-Driven Solutions Needed by the 121 Million Women and Girls Who Experience Unplanned Pregnancies Each Year Organon (NYSE: OGN), a global healthcare c...
2023-03-06 23:01:05 ET Summary Kahn Brothers’ 13F portfolio value increased from ~$642M to ~$760M this quarter. Most of the stakes saw minor adjustments during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ~49% o...
Organon Canada receives the Women in Governance (WiG) Parity Certification SME, further demonstrating its commitment to gender parity in the workplace Canada NewsWire The WiG evaluation, which comprises over 75 quantitative and qualitative criteria, showcases Organon Canada's ...
Sydney, Australia (ABN Newswire) - Moneghetti Minerals Limited (Moneghetti, the Company) today announced it has identified new high-priority drill targets at the Company's flagship Ecru Gold Project (Ecru) located in the well endowed Cortez District, Nevada USA. The Ecru Project is a Carlin-t...
Ahead of International Women's Day, Organon Canada Spotlights the Importance of Supporting Women's Equity While Highlighting the Cost of Not Investing in Their Health Canada NewsWire 170 employees across Canada will receive paid time off and join 10,000 Organon employees w...
Summary Merck has seen a significant valuation re-rating take place over the past years. This comes amidst the success of Keytruda, which creates some dependency risks as well. With no growth seen in 2023, amidst tough comparables from a pandemic-related contribution in 2022, I am a...
Shares of Organon (NYSE: OGN) fell 15% on Thursday. The pharmaceutical company, which focuses on women's health therapies, established medicines, and biosimilars, reported fourth-quarter and full-year numbers that came in below analysts' consensus expectations. The stock ended the session...
Organon & Co (OGN) Q4 2022 Earnings Conference Call February 16, 2023, 08:30 ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO & Director Matthew Walsh - EVP & CFO Conference Call Participants Terence Flynn - Morgan Stanley U...
Organon ( NYSE: OGN ) stock fell ~4% premarket on Thursday after Q4 results missed estimates. Q4 adjusted EPS declined -28.3% Y/Y to $0.81. Revenue fell -7.4% Y/Y to ~$1.49B but grew +1% Y/Y excluding the impact of foreign currency (ex-FX). "Since these products have been ...
Organon press release ( NYSE: OGN ): Q4 Non-GAAP EPS of $0.81 misses by $0.10 . Revenue of $1.49B (-6.9% Y/Y) misses by $10M . Shares -1.2% PM. Full year 2023 financial guidance provided; full year revenue range of $6.150 billion to $6.450 billion vs. $6.3...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, BC / ACCESSWIRE / July 31, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce a new significant gold-silver discovery, called the Navidad vein system, on the Ermitaño Mine concessions in Sonora, Mexico where the Company holds a...
VANCOUVER, BC / ACCESSWIRE / July 24, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties. Highlights Estimated 30,000 metres of drilling in seven planned or comp...
Company estimates $15 million of milestone expense in the second quarter Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its second quarter 2024 financial results on August 6, 2024, prior to the company’s webcast and conference...